Alector LLC

Pfizer Corporation

Merck Patent Gmbh

Hua Long

Jeonghoon Sun

Arnon Rosenthal

Wei-Hsien Ho

Tina Schwabe

Spencer Liang

Ilaria Tassi

Chia-Yang Lin

Herve Rhinn

Angie Grace Yee

Philip Ling Kong

David J Fontana

Muhammad Abbas Alhawagri

Ananya Mitra

Samuel Nalle

Shihao Chen

Glen Ian Andrews

Adrian Woolfson

Alessandra Di Pietro

Karpagam Srinivasan

Zelanna Goldberg

Santiago Viveros Salazar

Daniel P Bermingham

Francesca Cignarella

Marcella Martignoni

Klaus-Dieter Heger

Dimitry Serge Antoine Nuyten

Rashmi Bankoti

Aron David Thall

The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.

Siglec-9 ECD fusion molecules

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-MS4A4A antibodies and methods of use thereof

The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.

PD-L1 antagonist combination treatments

Growing community of inventors

San Carlos, CA, United States of America

Hua Long